-
Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study2020 Blood article Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Vaishali Sanchorawala, Giovanni O. Palladini, Monique C. Minnema, Arnaud Jaccard, Hans Chulhee Lee, Simon DJ Gibbs, +28 more
7citations -
The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients
Jenny Rinke, Philipp le Coutre, Martina Margrit Crysandt, Tim H. Brümmendorf, Andreas Burchert, Fabian Lang, +5 more
6citations -
GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness2021 Blood article Immunology and Microbiology Mast cells and histamine Open access cited by 1 patent
Julie Agopian, Quentin Da Costa, Quang Vo Nguyen, Giulia Scorrano, Paraskevi Kousteridou, Min Yuan, +11 more
6citations -
Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda2020 Blood article Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Ashutosh D. Wechalekar, Giovanni O. Palladini, Giampaolo Merlini, Raymond L. Comenzo, Arnaud Jaccard, NamPhuong Tran, +6 more
6citations -
Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial
Joost S.P. Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Yoon Cheah, Justin M. Darrah, +7 more
6citations -
Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial
Jörge E. Cortes, Philipp D. le Coutre, Carlo B Gambacorti-Passerini, Henrik Hjorth‐Hansen, Pia Raanani, Valentín García‐Gutiérrez, +5 more
5citations -
Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response
Susanne Isfort, Dominik Georg Friedrich Wolf, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +11 more
5citations -
Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
Christoph Röllig, Björn Steffen, Nael Alakel, Regina Herbst, Richard Noppeney, Maher Hanoun, +32 more
5citations -
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, +46 more
5citations -
Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Cell death mechanisms and regulation
Shukaib Arslan, Giovanni Marconi, Giovanni Martinelli, Shaun A. Fleming, Antonio Curti, Shira Naomi Dinner, +19 more
5citations -
Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Andrew Tucker Kuykendall, Aniket Bankar, Kristen Marie Pettit, Joseph James Shatzel, Alessandro Lucchesi, Valentín García‐Gutiérrez, +20 more
5citations